StockData

Actinium Pharmaceuticals vs Lisata Therapeutics

ATNM and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATNM and LSTA compare

Actinium Pharmaceuticals is the larger company, worth 4.5 times as much as Lisata Therapeutics ($42.4M against $9.4M).

Actinium Pharmaceuticals scores higher on the StockData Score (10 against 6 for Lisata Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATNMLSTA
Size and price
Market cap$42.4M$9.4M
Share price$1.35$1.04
Change, 1 year6.3%−50.9%
Change, 5 years−81.5%−92.9%
Beta (5Y)1.38−1.59
Employees2521
StockData Score
Total score10 (better)6
Valuation score4 (better)1
Growth score00
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/E3.8×–
P/S–93.7×
P/B1.4×1.1× (better)
EV/EBITDA0.6×–
FCF yield–−131%
Fair value$7.16–
Margin of safety81.1%–
Growth
Revenue growth (TTM)–−90.7%
Profitability
Operating margin–−16427%
Net margin–−14621%
FCF margin–−12323%
Return on equity45.9% (better)−99.9%
Return on invested capital–−1645%
Financial health
Debt / equity0.000.00
Current ratio4.08 (better)3.69
Altman Z-score−9.28 (better)−74.81
Piotroski F-score2 (better)1
Dividends and buybacks
Buyback yield–−6.3%
Shareholder yield0.00% (better)−6.3%
Ownership
Held by institutions16.8%12.1%
Held by insiders5.9%11.6%
Short interest, % of float2.0%0.43%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.